Try a new search

Format these results:

Searched for:

person:winnia01

Total Results:

16


The effect of race coefficients on preemptive listing for kidney transplantation

Abate, Mersema; Jandovitz, Nicholas; Hirsch, Jamie S; Breslin, Nadine; Lau, Lawrence; Fahmy, Ahmed E; Jhaveri, Kenar D; Richardson, Safiya; Alsalmay, Yaser; Baez, Anthony; Mishra, Akash; Bolourani, Siavash; Miyara, Santiago J; Winnick, Aaron; Nair, Gayatri; Bhaskaran, Madhu C; Grodstein, Elliot; Kressel, Adam M; Teperman, Lewis W; Molmenti, Ernesto P; Nair, Vinay
BACKGROUND/UNASSIGNED:Race coefficients of estimated glomerular filtration rate (eGFR) formulas may be partially responsible for racial inequality in preemptive listing for kidney transplantation. METHODS/UNASSIGNED:We used the Scientific Registry of Transplant Recipients database to evaluate differences in racial distribution of preemptive listing before and after application of the Modification of Diet in Renal Disease (MDRD) and the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) race coefficients to all preemptively listed non-Black kidney transplant candidates (eGFR modulation). Odds of preemptive listing were calculated by race, with Black as the reference before and after eGFR modulation. Variables known to influence preemptive listing were included in the model. RESULTS/UNASSIGNED:were removed. Compared with Black candidates, the adjusted odds of preemptive listing for White candidates decreased from 2.01 [95% confidence interval (95% CI) 1.78-2.26] before eGFR modulation to 1.18 (95% CI 1.0-1.39; P = 0.046) with the MDRD and 1.37 (95% CI 1.18-1.58) with the CKD-EPI equations after adjusting for race coefficients. CONCLUSIONS/UNASSIGNED:Removing race coefficients in GFR estimation formulas may result in a more equitable distribution of Black candidates listed earlier on a preemptive basis.
PMCID:9050544
PMID: 35498880
ISSN: 2048-8505
CID: 5394872

An early experience on the effect of solid organ transplant status on hospitalized COVID-19 patients

Nair, Vinay; Jandovitz, Nicholas; Hirsch, Jamie S; Abate, Mersema; Satapathy, Sanjaya K; Roth, Nitzan; Miyara, Santiago J; Guevara, Sara; Kressel, Adam M; Xiang, Alec; Wu, Grace; Butensky, Samuel D; Lin, David; Williams, Stephanie; Bhaskaran, Madhu C; Majure, David T; Grodstein, Elliot; Lau, Lawrence; Nair, Gayatri; Fahmy, Ahmed E; Winnick, Aaron; Breslin, Nadine; Berlinrut, Ilan; Molmenti, Christine; Becker, Lance B; Malhotra, Prashant; Gautam-Goyal, Pranisha; Lima, Brian; Maybaum, Simon; Shah, Samit K; Takegawa, Ryosuke; Hayashida, Kei; Shinozaki, Koichiro; Teperman, Lewis W; Molmenti, Ernesto P
We compared the outcome of COVID-19 in immunosuppressed solid organ transplant (SOT) patients to a transplant naïve population. In total, 10 356 adult hospital admissions for COVID-19 from March 1, 2020 to April 27, 2020 were analyzed. Data were collected on demographics, baseline clinical conditions, medications, immunosuppression, and COVID-19 course. Primary outcome was combined death or mechanical ventilation. We assessed the association between primary outcome and prognostic variables using bivariate and multivariate regression models. We also compared the primary endpoint in SOT patients to an age, gender, and comorbidity-matched control group. Bivariate analysis found transplant status, age, gender, race/ethnicity, body mass index, diabetes, hypertension, cardiovascular disease, COPD, and GFR <60 mL/min/1.73 m2 to be significant predictors of combined death or mechanical ventilation. After multivariate logistic regression analysis, SOT status had a trend toward significance (odds ratio [OR] 1.29; 95% CI 0.99-1.69, p = .06). Compared to an age, gender, and comorbidity-matched control group, SOT patients had a higher combined risk of death or mechanical ventilation (OR 1.34; 95% CI 1.03-1.74, p = .027).
PMID: 33443778
ISSN: 1600-6143
CID: 4747162

A Sustained Viral Response Achieved with Sofosbuvir/Ledipasvir May Increase the Incidence of Acute Cellular Rejection Post Liver Transplantation [Meeting Abstract]

Bortecen, K; Layman, R; Gelb, B; Winnick, A; Morgan, G; Tobias, H; Teperman, L
ISI:000383373902143
ISSN: 1600-6143
CID: 2386272

What Are the Charges and Costs of Transplanting High MELD Patients? [Meeting Abstract]

Bortecen, K; Gelb, B; Winnick, A; Morgan, G; Teperman, L
ISI:000383373902448
ISSN: 1600-6143
CID: 2386282

What are the true costs of transplanting high MELD patients? [Meeting Abstract]

Bortecen, K; Freitas, D; Bekisz, J; Gelb, B; Winnick, A; Morgan, G; Teperman, L
Purpose: There is a significant variation in the MELD scores and subsequent morbidity among liver recipients in the US. Larger OPOs consistently serve patients with advanced disease. Previous studies have shown 2.5 times greater prevalence of transplanted patients with MELD 3 24 in these OPOs. CMS recent reimbursement adjustments may disproportionately affect certain programs given their increased prevalence of patients with more advanced disease. Methods: We analyzed the prevalence of transplants among patients with high UNET MELD scores and associated charges, costs, and reimbursements. We compared low, medium and high MELD score groups. Between 2014-2015, 43 liver transplants, all with >30 days survival, were analyzed. Results: Only 2 had MELD scores below 25 at transplant, both of which from live donors. 95% of patients had MELD scores above 25 and among these, 18% had MELD 40 or were Status 1. Compared to the national average, our MELD scores were: 25% 21-30 (National 21.5%, p >0.05), 70.5% 31-40 (National 25.9%, p < 0.001), and 4.5% Status 1 (National 5.9%, p >0.05). For MELD scores 21-30, hospital charges averaged $645,214 and reimbursements were $150,706. For MELD scores 31-39, charges were $686,720, and reimbursement were $139,776. Reviewing MELD 40/ Status 1 patients, the average hospital charges and reimbursements were $1,136,813 and $293,776 respectively. We compared their amounts to the MELD 40 patients who had hospital charges of $625,371 and reimbursements of $142,051 respectively. This demonstrated a loss of $843,037 for the first group and $483,320 for the second. Length of stay was 32 days for MELD 40/ Status 1 and 8 days for MELD 40 (p < 0.000). Conclusion: 3 40 MELD patients have a huge financial impact on institutions. The difference between 25-39 and 340 MELD points is greater than half a million dollars. These data reflect and include dialysis, intubation and ICU stay but do not include rehabilitation expenses which will be the focus of another study. We find that our institution, which likely reflects many institutions in our OPO, serves sicker patients and therefore incurs higher costs but receives lower reimbursements, as they are based on national expected care costs for healthier patients. A broader sharing in the US may equalize costs. Payers should take into account the added financial burden of performing transplant in high MELD patients
EMBASE:614325724
ISSN: 0041-1337
CID: 2454462

An Excellent Sustained Viral Response Is Achieved in Post Liver Transplant HCV Recipients Using Sofosbuvir/Ribavirin [Meeting Abstract]

Hamshow, M; Bortecen, K; Winnick, A; Gelb, B; Morgan, G; Teperman, L
ISI:000368626500417
ISSN: 1534-6080
CID: 1989332

A Simple PTC Taste Test Is a Cost-Effective Adjunct To the Current Selection Criteria for Liver Transplantation [Meeting Abstract]

Bortecen, K; Hamshow, M; Gelb, B; Winnick, A; Morgan, G; Teperman, L
ISI:000368626500521
ISSN: 1534-6080
CID: 1989562

Interferon-Free Sofosvir/Ribavirin Treatment Achieves Excellent Sustained Viral Response in Post Liver Transplant HCV Recipients [Meeting Abstract]

Hamshow, M; Bortecen, K; Layman, R; Winnick, A; Gelb, B; Morgan, G; Teperman, L
ISI:000370124201050
ISSN: 1600-6143
CID: 2049032

Porto-Arterial Fistula Creation as a Complication of TIPS Procedure Causing Occult GI Bleeding [Meeting Abstract]

Benasher, Daniel; Cheung, Derrick; Teagle, Kelly; Anyadike, Nnaemeka; Iswara, Kadirawel; Park, James; Winnick, Aaron; Sobolevsky, Sergei; Mobley, David; Rahmani, Rabin; Mayer, Ira
ISI:000344383100531
ISSN: 0002-9270
CID: 5274102

Cecal Bascule: A Rare Adverse Event as a Result of Retuximab Therapy [Meeting Abstract]

Khodorskiy, Dmitriy; Cheung, Derrick; Winnick, Aaron; Serur, Anna; Jan, Samah; Mayer, Ira; Rahmani, Rabin
ISI:000330178101403
ISSN: 1572-0241
CID: 2109492